目的 探討復(fù)方斑蝥膠囊聯(lián)合吉非替尼治療非小細(xì)胞肺癌（NSCLC）的臨床療效。方法 選取2015年7月—2017年7月在內(nèi)蒙古自治區(qū)人民醫(yī)院接受治療的非小細(xì)胞肺癌患者80例，隨機(jī)分為對(duì)照組和治療組，每組各40例。對(duì)照組患者口服吉非替尼片治療，0.25 g/d；治療組患者在對(duì)照組的基礎(chǔ)上口服復(fù)方斑蝥膠囊，3粒/次，2次/d。兩組患者連續(xù)治療9周。評(píng)價(jià)兩組臨床療效，同時(shí)比較治療前后兩組患者免疫功能、血清可溶性白細(xì)胞介素-2受體（SIL-2R）、腫瘤特異性生長(zhǎng)因子（TSGF）、血管內(nèi)皮生長(zhǎng)因子（VEGF）水平變化情況。結(jié)果 治療后，對(duì)照組臨床有效率和疾病控制率分別為20.00%、60.00%，均明顯低于治療組的30.00%、82.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者IgA、IgG、IgM表達(dá)水平均低于治療前（P<0.05），且治療后治療組者IgA和IgG水平低于對(duì)照組（P<0.05）。治療后，兩組患者血清SIL-2R、TSGF表達(dá)水平明顯下降（P<0.05），VEGF表達(dá)水平明顯升高（P<0.05）；且治療后治療組患者血清SIL-2R、TSGF和VEGF水平明顯好于對(duì)照組（P<0.05）。結(jié)論 復(fù)方斑蝥膠囊配合吉非替尼治療可明顯提高對(duì)NSCLC的控制率，且安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate effect of Compound Banmao Capsules combined with gefitinib in treatment of non-small cell lung cancer. Methods Patients (142 cases) with non-small cell lung cancer in the Inner Mongolia Autonomous Region People's Hospital from July 2015 to July 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Gefitinib Tablets, 0.25 g/d. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 9 weeks. After treatment, the clinical efficacy was evaluated, and the immune function, SIL-2R, TSGF and VEGF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and disease control rate in the control group were 20.00% and 60.00%, which were significantly lower than 30.00% and 82.50% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the IgA, IgG and IgM levels in two groups were significantly decreased (P < 0.05), and the IgA, IgG levels in the treatment group after treatment were significantly lower than that in the control group (P < 0.05). After treatment, the SIL-2R and TSGF levels in two groups were significantly decreased (P < 0.05), the VEGF levels were significantly increased (P < 0.05). And the serum SIL-2R, TSGF and VEGF levels in the treatment group after treatment were significantly better than those in the control group (P < 0.05). Conclusion Compound Banmao Capsules combined with gefitinib can significantly improve the control rate of NSCLC in treatment of non-small cell lung cancer with high safety, which has a certain clinical application value.